The 4Kscore test is a non‐invasive blood based test that provides a second decision point prior to a prostate biopsy after an abnormal PSA and/or digital rectal examination. It provides an accurate risk of aggressive prostate cancer, allowing for early detection of high risk men, while reducing the number of unnecessary prostate biopsies. It has been shown to categorize long term risk of distant metastasis in men with an elevated PSA, and is included in NCCN guidelines for Prostate Cancer Early Detection. Use of the 4Kscore will reduce the costs and complications of unnecessary prostate biopsies, while identifying men at a higher risk of aggressive cancer, who would benefit from more extensive evaluation.
Ready to learn more?
Click here to contact us, and our team will be in touch.
Learn how the 4Kscore measures a patient’s risk for aggressive prostate cancer
1. Parekh DJ, Punnen S, Sjoberg DD, et al. A multi‐institutional prospective trial in the USA confirms that the 4Kscore accurately identifies men with high‐grade prostate cancer. Eur Urol. 2015 Sep;68(3):464‐70.
2. Stattin P, Vickers AJ, Sjoberg DD et al. Improving the specificity of screening for lethal prostate cancer using prostate‐specific antigen and a panel of kallikrein markers: a nested case–control study. Eur Urol. 2015 Aug;68(2):207‐13.
3. Konety, B., Zappala, S., Parekh, D., et al. “The 4Kscore® Test Reduces Prostate Biopsy Rates in Community and Academic Urology Practices.” Reviews in urology 17.4 (2015): 231.